Skip to main content
SpringerLink
Log in

Management of Gastrointestinal Motility Disorders

A Practical Guide to Drug Selection and Appropriate Ancillary Measures

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The focus of management of gastrointestinal motility disorders should be to improve survival and quality of life. Some motor disorders are annoying, but are compatible with virtually normal activity and carry no significant life risk. Conversely, other motor disorders are highly incapacitating and may shorten life expectancy because of complications and nutritional impairment. Management is based first on establishing the correct diagnosis and prognosis; secondly, on adjusting therapy to the severity of illness; and thirdly, on preventing significant complications. Simple recommendations on appropriate changes in lifestyle and reassurance may suffice in mild cases. Pharmacological therapy and, exceptionally, surgical or nutritional measures may be required in other patients. Generally, pharmacological agents should be directed towards correcting specific patho-physiological abnormalities, but this is not always possible. Symptomatic relief may be achieved on an empirical basis. Long term treatment may often require the combination of different therapeutic approaches either sequentially or simultaneously.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Janssens J, Vantrappen G, Ghillebert G. 24-hour recording of esophageal pressure and pH in patients with noncardiac chest pain. Gastroenterology 1986; 90: 1978–84

    PubMed  CAS  Google Scholar 

  2. Peters L, Maas L, Petty D, et al. Spontaneous noncardiac chest pain: evaluation by 24-hour ambulatory esophageal motility and pH monitoring. Gastroenterology 1988; 94: 878–86

    PubMed  CAS  Google Scholar 

  3. Breumelhof R, Nadorp JHSM, Akkermans LMA, et al. Analysis of 24-hour esophageal pressure and pH data in unselected patients with noncardiac chest pain. Gastroenterology 1990; 99: 1257–64

    PubMed  CAS  Google Scholar 

  4. Soffer EE, Scalabrini P, Wingate DL. Spontaneous noncardiac chest pain: value of ambulatory esophageal pH and motility monitoring. Dig Dis Sci 1989; 34: 1651–5

    Article  PubMed  CAS  Google Scholar 

  5. Schindlbeck NE, Klauser AG, Voderholzer WA, et al. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155: 1808–12

    Article  PubMed  CAS  Google Scholar 

  6. Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49: 695–710

    Article  PubMed  CAS  Google Scholar 

  7. Vantrappen G, Janssens J, Ghillebert G. The irritable oesophagus — a frequent cause of angina-like pain. Lancet 1987; I: 1232–4

    Article  Google Scholar 

  8. Allen M, Mellow M, Robinson MG, et al. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment Pharmacol Ther 1987; 1: 153–9

    Article  PubMed  CAS  Google Scholar 

  9. Konrad-Dalhoff I, Baunack AR, Ramsch KD, et al. Effect of calcium antagonists nifedipine, nitrendipine, nimodipine and nisoldipine on oesophageal motility in man. Eur J Clin Pharmacol 1991; 41: 313–6

    Article  PubMed  CAS  Google Scholar 

  10. Cattau Jr EL, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86: 272–6

    PubMed  Google Scholar 

  11. Triadafilopoulos G, Aaronson M, Sackel S, et al. Medical treatment of esophageal achalasia: double-blind crossover study with oral nifedipine, verapamil and placebo. Dig Dis Sci 1991; 36: 260–7

    Article  PubMed  CAS  Google Scholar 

  12. Bortolotti M, Coccia G, Brunelli F, et al. Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia? Ital J Gastroenterol 1994; 26: 379–82

    PubMed  CAS  Google Scholar 

  13. Achem-Karam SR, Kolts BE. Current medical therapy for esophageal motility disorders. Am J Med 1992; 92: 98S–105S

    Article  Google Scholar 

  14. Peterson WG, Selucky M, Hynna-Liepert TT. Effect of intraesophageal location and muscarinic blockade on balloon distension-induced chest pain. Dig Dis Sci 1991; 36: 282–8

    Article  Google Scholar 

  15. Bassotti G, Gaburri M, Imbimbo PB, et al. Manometric evaluation of cimetropium bromide activity in patients with nutcracker oesophagus. Scand J Gastroenterol 1988; 23: 1079–84

    Article  PubMed  CAS  Google Scholar 

  16. Marzio L, Pieramico O, Neri M, et al. Comparative study of the effects of cimetropium bromide and atropine on human esophageal motor functions. Digestion 1989; 44: 117–23

    Article  PubMed  CAS  Google Scholar 

  17. Marzio L, Grossi L, DeLaurentis MF, et al. Effect of cimetropium bromide on esophageal motility and transit in patients affected by primary achalasia. Dig Dis Sci 1994; 39: 1389–94

    Article  PubMed  CAS  Google Scholar 

  18. Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci 1989; 34: 1600–1605

    Article  PubMed  CAS  Google Scholar 

  19. Robertson CS, Evans DF, Ledingham SJ, et al. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 181–90

    Article  PubMed  CAS  Google Scholar 

  20. Bost R, Hostein J, Carpentier P, et al. Effects of cisapride on oesophageal motility patterns in systemic sclerosis. Eur J Gastroenterol Hepatol 1992; 4: 323–8

    Google Scholar 

  21. Wienbeck M, Li Q. Cisapride on gastro-oesophageal reflux disease: effects on oesophageal motility and intra-oesophageal pH. Scand J Gastroenterol 1989; 24(Suppl. 165): 13–8

    Article  Google Scholar 

  22. Achem-Karam SR, Funakoshi A, Vinik AI, et al. Plasma motilin concentration and interdigestive migrating motor complex in diabetic gastroparesis: effect of metoclopramide. Gastroenterology 1985; 88: 492–9

    PubMed  CAS  Google Scholar 

  23. McCallum RW, Valenzuela GA, Polepalle S, et al. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther 1991; 258: 136–42

    PubMed  CAS  Google Scholar 

  24. McHugh S, Lico S, Diamant NE. Cisapride vs metoclopramide: an acute study in diabetic gastroparesis. Dig Dis Sci 1992; 37: 997–1001

    Article  PubMed  CAS  Google Scholar 

  25. Nelson KA, Walsh TD. Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS). J Palliat Care 1993; 9: 14–8

    PubMed  CAS  Google Scholar 

  26. Drenth JP, Engels LG. Diabetic gastroparesis: a critical reappraisal of new treatment strategies. Drugs 1992; 44: 537–53

    Article  PubMed  CAS  Google Scholar 

  27. Takeda K, Taniyama K, Kuno T, et al. Clebopride enhances contractility of the guinea pig stomach by blocking peripheral D2 dopamine receptor and alpha-2 adrenoceptors. J Pharmacol Exp Ther 1991; 257: 806–11

    PubMed  CAS  Google Scholar 

  28. Bleiberg H, Piccart M, Lips S, et al. A phase I trial of a new antiemetic drug — clebopride malate — in cisplatinum-treated patients. Ann Oncol 1992; 3: 141–3

    PubMed  CAS  Google Scholar 

  29. Sabbatini F, Minieri M, Manzi G, et al. Clinical efficacy anf safety of cisapride and clebopride in the managment of chronic functional dyspepsia: a double-blind, randomized study. Ital J Gastroenterol 1991; 23: 1–4

    PubMed  CAS  Google Scholar 

  30. Arienti V, Corazza GR, Sorge M, et al. The effects of levosulpiride on gastric and gallbladder emptying in functional dyspepsia. Aliment Pharmacol Ther 1994; 8: 631–8

    Article  PubMed  CAS  Google Scholar 

  31. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 1–9

    Article  PubMed  CAS  Google Scholar 

  32. Feldman M, Smith HJ. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum: a comparison with metoclopramide and placebo. Gastroenterology 1987; 92: 171–4

    PubMed  CAS  Google Scholar 

  33. Camilleri M, Malagelada J-R, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989; 96: 704–12

    PubMed  CAS  Google Scholar 

  34. Fraser R, Horowitz M, Maddox A, et al. Dual effects of cisapride on gastric emptying and antropyloroduodenal motility. Am J Physiol 1993; 264: G195–201

    PubMed  CAS  Google Scholar 

  35. Kawagishi T, Nishizawa Y, Okuno Y, et al. Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomic neuropathy. Am J Gastroenterol 1993; 88: 933–8

    PubMed  CAS  Google Scholar 

  36. Richards RD, Valenzuela GA, Davenport KG, et al. Objective and subjective results of a randomized, double-blind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993; 38: 811–6

    Article  PubMed  CAS  Google Scholar 

  37. Gullikson GW, Virina MA, Loeffler R, et al. Alpha 2-adrenergic model of gastroparesis: validation with renzapride, a stimulatory of motility. Am J Physiol 1991; 261: G426–32

    PubMed  CAS  Google Scholar 

  38. Mackie AD, Ferrington C, Cowan S, et al. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991; 5: 135–42

    Article  PubMed  CAS  Google Scholar 

  39. Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991; 36: 616–20

    Article  PubMed  CAS  Google Scholar 

  40. Corinaldesi R, Stanghellini V, Tosetti C, et al. The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993; 44: 429–32

    Article  PubMed  CAS  Google Scholar 

  41. Dworkin BM, Rosenthal WS, Casellas AR, et al. Open label study of long-term effectiveness of cisapride in patients with idiopathic gastroparesis. Dig Dis Sci 1994; 39: 1395–8

    Article  PubMed  CAS  Google Scholar 

  42. Muller Lissner SA, Fraas C, Hartl A. Cisapride offsets dopamine-induced slowing of fasting gastric emptying. Dig Dis Sci 1986; 31: 807–10

    Article  PubMed  CAS  Google Scholar 

  43. Djaldetti R, Koren M, Ziv I, et al. Effect of cisapride on response fluctuations in Parkinson’s disease. Mov Disord 1995; 10: 81–4

    Article  PubMed  CAS  Google Scholar 

  44. Bran S, Murray WA, Hirsch IB, et al. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 765–8

    Article  PubMed  CAS  Google Scholar 

  45. Kendall BJ, McCallum RW. Gastroparesis and the current use of prokinetic drugs. Gastroenterologist 1993; 1: 107–14

    PubMed  CAS  Google Scholar 

  46. Fiorucci S, Bosso R, Morelli A. Erythromycin stimulates gallbladder emptying and motilin release by an atropine sensitive pathway. Dig Dis Sci 1992; 37: 1678–83

    Article  PubMed  CAS  Google Scholar 

  47. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990; 322: 1028–31

    Article  PubMed  CAS  Google Scholar 

  48. Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992; 33: 397–401

    Article  PubMed  CAS  Google Scholar 

  49. Nakamura T, Ishii M, Arai Y, et al. Effect of intravenous administration of EM523L on gastric emptying and plasma glucose levels after a meal in patients with diabetic gastroparesis: a pilot study. Clin Ther 1994; 16: 989–99

    PubMed  CAS  Google Scholar 

  50. Rosa-e-Silva L, Troncon LE, Oliveira RB, et al. Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995; 9: 179–83

    Article  PubMed  CAS  Google Scholar 

  51. Fioramonti J, Soldani G, Houde C, et al. Effect of ranitidine and oxmetadine on gastrointestinal motility in conscious dog. Agents Actions 1984; 15: 260–3

    Article  PubMed  CAS  Google Scholar 

  52. Bortolotti M, Cucchiara S, Sarti P, et al. Interdigestive gastroduodenal motility in patients with ulcer-like dyspepsia: effect of ranitidine. Hepatogastroenterology 1992; 39: 31–3

    PubMed  CAS  Google Scholar 

  53. Bortolotti M, Cucchiara S, Sarti P, et al. Comparison between the effects of neostigmine and ranitidine on interdigestive gastroduodenal motility of patients with gastroparesis. Digestion 1995; 56: 96–9

    Article  PubMed  CAS  Google Scholar 

  54. Bertaccini G, Scarpignato C. Histamine H2-antagonists modify gastric emptying in the rat. Br J Pharmacol 1982; 77: 443–8

    Article  PubMed  CAS  Google Scholar 

  55. Sasho S, Obase H, Ichikawa S, et al. Synthesis of 2-imidazolidinylidenepropanedinitrile derivatives as stimulators of gastrointestinal motility. J Med Chem 1993; 36: 572–9

    Article  PubMed  CAS  Google Scholar 

  56. McCallum RW, Polepalle SC, Schirmer B. Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease: long-term follow-up with subjective and objective parameters. Dig Dis Sci 1991; 36: 1556–61

    Article  PubMed  CAS  Google Scholar 

  57. Christensen J, Dent J, Malagelada J-R, et al. Pseudo-obstruction. Gastroenterol Int 1990; 3: 107–19

    Google Scholar 

  58. Pitt HA, Mann LL, Berquist WE, et al. Chronic intestinal pseudo-obstruction: management with total parenteral nutrition and a venting enterostomy. Arch Surg 1985; 120: 614–8

    Article  PubMed  CAS  Google Scholar 

  59. Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudoobstruction syndrome in pediatrics: results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1988; 7: 323–32

    Article  PubMed  CAS  Google Scholar 

  60. Warner E, Jeejeebhoy KN. Successful management of chronic intestinal pseudo-obstruction with home parenteral nutrition. J Parent Enter Nutr 1985; 9: 173–8

    Article  CAS  Google Scholar 

  61. Moukarzel AA, Haddad I, Ament ME, et al. 230 patient years of experience with home long-term parenteral nutrition in childhood: natural history and life of central venous catheters. J Pediatr Surg 1994; 29: 1323–7

    Article  PubMed  CAS  Google Scholar 

  62. Roger R, Cerda J. The narcotic bowel syndrome. J Clin Gastroenterol 1989; 11: 132–5

    Article  Google Scholar 

  63. Cappell MS, Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol 1993; 88: 1684–9

    PubMed  CAS  Google Scholar 

  64. Sandgren JE, McPhee MS, Greenberger NJ. Narcotic bowel syndrome treated with clonidine: resolution of abdominal pain and intestinal pseudo-obstruction. Ann Intern Med 1984; 101: 331–4

    PubMed  CAS  Google Scholar 

  65. Schang JC, Devroede G. Beneficial effects of naloxone in patients with intestinal pseudo-obstruction. Am J Gastroenterol 1985; 80: 407–11

    PubMed  CAS  Google Scholar 

  66. Keshavarzian A, Isaacs P, McColl I, et al. Idiopathic intestinal pseudo-obstruction and contaminated small bowel syndrome-treatment with metronidazole, ileostomy, and indomethacin. Am J Gastroenterol 1983; 78: 562–5

    PubMed  CAS  Google Scholar 

  67. Luderer JR, Demers LM, Bonnem EM, et al. Elevated prostaglandin E in idiopathic intestinal pseudo-obstruction. N Engl J Med 1976; 295: 1179

    Article  PubMed  CAS  Google Scholar 

  68. Soffer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci 1994; 39: 929–33

    Article  PubMed  CAS  Google Scholar 

  69. Roarty TP, Yeaton P, McCallum RW. High dose misoprostol in the successful treatment of acquired megacolon in a 23 year old man. Am J Gastroenterol 1994; 89: 1746

    Google Scholar 

  70. Casella F, Malagelada J-R. Diarrhea due to bacterial overgrowth and motility disorders. In: Winawer SJ, editor. Management of gastrointestinal disorders. New York: Raven Press, 1992; 15.1–18

    Google Scholar 

  71. McCallum RW. Cisapride: a new class of prokinetic agent. Am J Gastroenterol 1991; 86: 135–49

    PubMed  CAS  Google Scholar 

  72. Camilleri M, Brown ML, Malagelada J-R. Impaired transit of chyme in chronic intestinal pseudo-obstruction: correction with cisapride. Gastroenterology 1986; 91: 619–26

    PubMed  CAS  Google Scholar 

  73. Di Lorenzo C, Reddy SN, Villanueva-Meyer J, et al. Cisapride in children with chronic intestinal pseudoobstruction: an acute, double-blind, crossover, placebo-controlled trial. Gastroenterology 1991; 101: 1564–70

    PubMed  Google Scholar 

  74. Stanghellini V, Corinaldesi R, Ghidini C, et al. Reversibility of gastrointestinal motor abnormalities in chronic intestinal pseudo-obstruction. Hepatogastroenterology 1992; 39: 34–8

    PubMed  CAS  Google Scholar 

  75. Camilleri M, Balm RK, Zinsmeister AR. Influence of neurologic dysfunction on response to cisapride in adults with chronic intestinal pseudo-obstruction [abstract]. Gastroenterology 1993; 104: A486

    Google Scholar 

  76. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265–82

    Article  PubMed  CAS  Google Scholar 

  77. Benson MJ, Roberts JP, Wingate DL. Cisapride cover enhances post-operative antral motility and hastens recovery from ileus [abstract]. Gastroenterology 1994; 106: A466

    Google Scholar 

  78. Wiseman LR, Faulds D. Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116–52

    Article  PubMed  CAS  Google Scholar 

  79. Hyman PE, Di Lorenzo C, McAdams L, et al. Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastroenterol 1993; 88: 832–6

    PubMed  CAS  Google Scholar 

  80. Camilleri M, Balm RK, Zinsmeister AR. Determinants of response to a prokinetic agent in neurophatic chronic intestinal motility. Gastroenterology 1994; 106: 916–23

    PubMed  CAS  Google Scholar 

  81. Armstrong DN, Ballantyne GH, Modlin IM. Erythromycin for reflex ileus in Olgivie’s syndrome. Lancet 1991; 337: 378

    Article  PubMed  CAS  Google Scholar 

  82. Miller SM, O’Dorisio TM, Thomas FB, et al. Erythromycin exerts a prokinetic effect in patients with chronic idiopathic intestinal pseudo-obstruction [abstract]. Gastroenterology 1990; 98: A375

    Article  Google Scholar 

  83. Fiorucci S, Distrutti E, Gerli R, et al. Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is mantained medium term. Am J Gastroenterol 1994; 89: 550–5

    PubMed  CAS  Google Scholar 

  84. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461–9

    Article  PubMed  CAS  Google Scholar 

  85. von der Ohe MR, Camilleri M, Thomforde GM, et al. Differ ential regional effects of octreotide on human gastrointestinal motor function. Gut 1995; 36: 743–8

    Article  PubMed  Google Scholar 

  86. Edmunds MC, Chen JD, Lin Z, et al. The effect of octreotide on postprandial antral motility in patients with idiopathic gastroparesis [abstract]. Gastroenterology 1994; 107: A1246

    Google Scholar 

  87. Di Lorenzo C, Flores AF, Rehm D, et al. Octreotide induces MMCs which persist after feeding in children with enteric neuromuscolar disease (END) [abstract]. Gastroenterology 1994; 107:A1246

    Google Scholar 

  88. Verne GN, Eaker EY, Hardy E, et al. Use of octreotide and gastrointestinal manometry in idiopathic chronic intestinal pseudo-obstruction [abstract]. Gastroenterology 1994; 106: A584

    Google Scholar 

  89. Stolk MFJ, van Erpecum KJ, Koppeschaar HPF, et al. Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly. Gut 1995; 36: 755–60

    Article  PubMed  CAS  Google Scholar 

  90. Haruma K, Wiste JA, Camilleri M. Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. Gut 1994; 35: 1064–9

    Article  PubMed  CAS  Google Scholar 

  91. Freilich HS, Chopra S, Gilliam JI. Acute colonic pseudo-obstruction or Olgivie’s syndrome: report of two cases treated with colonscopic decompression and review of the literature. J Clin Gastroenterol 1986; 8: 457–60

    Article  PubMed  CAS  Google Scholar 

  92. Nano D, Prindiville T, Pauly M, et al. Colonscopic therapy of acute pseudo-obstruction on the colon. Am J Gastroenterol 1987; 82: 145–8

    PubMed  CAS  Google Scholar 

  93. Murr MM, Sarr MG, Camilleri M. The surgeon’s role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol 1995; 90: 2147–51

    PubMed  CAS  Google Scholar 

  94. Mughal MM, Irving MH. Treatment of end stage chronic intestinal pseudoobstruction by subtotal enterectomy and home parenteral nutrition. Gut 1988; 29: 1613–7

    Article  PubMed  CAS  Google Scholar 

  95. Mansell PI, Tattersall RB, Balsitis M. Megaduodenum due to hollow visceral myopathy successfully managed by duodenoplasty and feeding jejunostomy. Gut 1991; 32: 334–7

    Article  PubMed  CAS  Google Scholar 

  96. Todo S, Tzakis A, Reyes J, et al. Intestinal transplantation at the University of Pittsburgh. Transplant Proc 1994; 26: 1409–10

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive System Research Unit, Hospital General Universitari Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain

    Juan-R. Malagelada & Eleonora Distrutti

  2. Clinica di Gastroenterologia ed Endoscopia Digestiva, Università degli Studi di Perugia, Perugia, Italy

    Eleonora Distrutti

Authors
  1. Juan-R. Malagelada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleonora Distrutti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malagelada, JR., Distrutti, E. Management of Gastrointestinal Motility Disorders. Drugs 52, 494–506 (1996). https://doi.org/10.2165/00003495-199652040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652040-00003

Keywords

Search

Navigation